Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VITAL: A Pivotal Phase 3 Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GENE TRANSFER)

Next Previous
Trial Profile

VITAL: A Pivotal Phase 3 Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GENE TRANSFER)

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2018

At a glance

  • Drugs EB 101 (Primary)
  • Indications Epidermolysis bullosa
  • Focus Registrational; Therapeutic Use
  • Acronyms VITAL
  • Sponsors Abeona therapeutics

    • Most Recent Events

    • 06 Dec 2018 Planned initiation date changed from 1 Oct 2018 to 1 Jun 2019, according to an Abeona Therapeutics media release.
    • 06 Dec 2018 According to an Abeona Therapeutics media release, the company is planning to this study later in the middle of 2019.
    • 23 Aug 2018 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top